March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Post-NAION Demyelination: Treatment Targeting
Author Affiliations & Notes
  • Steven L. Bernstein
    Ophthalmology,
    Univ of Maryland Sch of Medicine, Baltimore, Maryland
  • Bernard J. Slater
    Anatomy, University of Illinois, Champaign, Illinois
  • Yan Guo
    Ophthalmology,
    Univ of Maryland Sch of Medicine, Baltimore, Maryland
  • Yan Guo
    Ophthalmology,
    Univ of Maryland Sch of Medicine, Baltimore, Maryland
  • Fernandino L. Vilson
    Ophthalmology, Univ of Maryland School of Med, Baltimore, Maryland
  • Danny Weinreich
    Pharmacology,
    Univ of Maryland Sch of Medicine, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  Steven L. Bernstein, Patent (P); Bernard J. Slater, None; Yan Guo, None; Yan Guo, None; Fernandino L. Vilson, None; Danny Weinreich, None
  • Footnotes
    Support  NEI RO1-EY015304
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3163. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Steven L. Bernstein, Bernard J. Slater, Yan Guo, Yan Guo, Fernandino L. Vilson, Danny Weinreich; Post-NAION Demyelination: Treatment Targeting. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3163.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Post-stroke demyelination is well known to occur in CNS infarcts, and recovery from this process may be important clinically. Post-NAION inflammation is a key component in NAION and its models (Salgado and Vilson et al, Arch. Ophth. 2011), and inflammatory modulation can play a role in ON damage and recovery (Nakazawa et al, J. Neurosci. 2006). We looked at post-infarct demyelination in models of nonarteritic anterior ischemic optic neuropathy (NAION), and evaluated whether modifying post-stroke inflammation is a useful target for enhancing post-NAION recovery.

Methods: : We analyzed both primate and rodent ONs for demyelination immuno-histochemically following NAION model induction, and ultrastructurally using transmission electron microscopy (TEM). Real-time quantitative PCR (rq-PCR) was used to evaluate oligodendrocyte-associated gene expression. We evaluated rodent ON function by compound action potentials (CAPs) in isolated ON preps of control and infarcted ONs. The cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) was injected intraventricularly 3 days post-infarct induction, at the peak of inflammatory response.

Results: : TEM reveals that there was a considerable demyelinating component following rAION induction, This demyelination is in excess of axonal loss, and detectable immunohistochemically using the intra-neural difference between intact axons and oligodendrocytes. CAP analysis revealed a significant functional component of post-AION demyelination, which was reversible at 30 days post-stroke using GM-CSF.

Conclusions: : Post-ischemic demyelination plays a significant role in NAION models, and likely in clinical NAION. The reversible portion of this phenomenon may contribute to the sizable number of patients that show clinical recovery following an episode of NAION. Agents such as GM-CSF directed at this mechanism may be useful in improving recovery from NAION, even when administered at times distant (>3 days) from the onset of the disease.

Keywords: optic nerve • immunomodulation/immunoregulation • neuroprotection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×